Analyzing Entrada Therapeutics (NASDAQ:TRDA) and Alvotech (NASDAQ:ALVO)

Alvotech (NASDAQ:ALVO – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Profitability

This table compares Alvotech and Entrada Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alvotech -50.62% N/A -11.71%
Entrada Therapeutics -4,057.98% -64.00% -50.49%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Alvotech and Entrada Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech 2 0 5 0 2.43
Entrada Therapeutics 1 2 4 0 2.43

Alvotech presently has a consensus target price of $8.40, suggesting a potential upside of 84.62%. Entrada Therapeutics has a consensus target price of $16.75, suggesting a potential upside of 233.00%. Given Entrada Therapeutics’ higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Alvotech.

Risk & Volatility

Alvotech has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.

Institutional & Insider Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Alvotech and Entrada Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alvotech $588.90 million 2.33 $27.92 million ($0.82) -5.55
Entrada Therapeutics $25.42 million 7.75 -$143.75 million ($3.84) -1.31

Alvotech has higher revenue and earnings than Entrada Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Alvotech beats Entrada Therapeutics on 8 of the 12 factors compared between the two stocks.

About Alvotech

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.